标题
Radiotheranostics in oncology: current challenges and emerging opportunities
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume 19, Issue 8, Pages 534-550
出版商
Springer Science and Business Media LLC
发表日期
2022-06-21
DOI
10.1038/s41571-022-00652-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds
- (2022) M. Weber et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial
- (2022) Jonathan D Schoenfeld et al. LANCET ONCOLOGY
- Efficacy and Safety of 225Ac-PSMA-617-Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
- (2022) Jiao Ma et al. Frontiers in Oncology
- The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective
- (2022) Sze Ting Lee et al. JOURNAL OF NUCLEAR MEDICINE
- Joint EANM, SNMMI and IAEA Enabling Guide: How to Set Up a Theranostics Centre
- (2022) Ken Herrmann et al. JOURNAL OF NUCLEAR MEDICINE
- Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis
- (2022) Kerstin N Vokinger et al. LANCET ONCOLOGY
- Theranostics could be big business in precision oncology
- (2022) Carrie Arnold NATURE MEDICINE
- Pharmacogenomics in Radionuclide Therapy: Impact on Response to Theranostics
- (2021) Andrew Scott et al. JOURNAL OF NUCLEAR MEDICINE
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate-Specific Membrane Antigen PET/CT with 18 F-DCFPyL in Prostate Cancer Patients (OSPREY)
- (2021) Kenneth J. Pienta et al. JOURNAL OF UROLOGY
- [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
- (2021) Michael S Hofman et al. LANCET
- Medical imaging and nuclear medicine: a Lancet Oncology Commission
- (2021) Hedvig Hricak et al. LANCET ONCOLOGY
- Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
- (2021) Avi Cherla et al. JAMA Internal Medicine
- Updating Reports of Phase 3 Clinical Trials for Cancer
- (2021) Elena Elimova et al. JAMA Oncology
- Radio-Iodide Treatment: From Molecular Aspects to the Clinical View
- (2021) Antonio De la Vieja et al. Cancers
- Personalised dosimetry for SIRT: new standard or bridge to surgical resection? – Authors' reply
- (2021) Etienne Garin et al. Lancet Gastroenterology & Hepatology
- 577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)
- (2021) S.K. Sandhu et al. ANNALS OF ONCOLOGY
- Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set
- (2021) E.A. Klein et al. ANNALS OF ONCOLOGY
- Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial
- (2021) Ugo De Giorgi et al. BRITISH JOURNAL OF CANCER
- An urgent call to raise the bar in oncology
- (2021) John-John B. Schnog et al. BRITISH JOURNAL OF CANCER
- Immunogenic priming with 177Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): A phase 1b study.
- (2021) Rahul Raj Aggarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial
- (2021) Mary F. Mulcahy et al. JOURNAL OF CLINICAL ONCOLOGY
- Feasibility, Biodistribution and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy (PTRT) of Diverse Adenocarcinomas using 177Lu-FAP-2286: First-in-Human Results
- (2021) Richard P Baum et al. JOURNAL OF NUCLEAR MEDICINE
- Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
- (2021) Sonya Youngju Park et al. JOURNAL OF NUCLEAR MEDICINE
- ‘J’accuse.!’: the continuous failure to address radiophobia and placing radiation in perspective
- (2021) John C H Lindberg JOURNAL OF RADIOLOGICAL PROTECTION
- Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report
- (2021) Skyler B Johnson et al. JNCI-Journal of the National Cancer Institute
- Microspheres Used in Liver Radioembolization: From Conception to Clinical Effects
- (2021) Philippe d’Abadie et al. MOLECULES
- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
- (2021) Oliver Sartor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical correlates of circulating cell-free DNA tumor fraction
- (2021) Joerg Bredno et al. PLoS One
- Kidney Protection with the Radical Scavenger α1-Microglobulin (A1M) during Peptide Receptor Radionuclide and Radioligand Therapy
- (2021) Amanda Kristiansson et al. Antioxidants
- Revisiting the Radiobiology of Targeted Alpha Therapy
- (2021) Jean-Pierre Pouget et al. Frontiers in Medicine
- 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
- (2021) Jonathan R Strosberg et al. LANCET ONCOLOGY
- From the target cell theory to a more integrated view of radiobiology in Targeted radionuclide therapy: The Montpellier group's experience
- (2021) Jean-Pierre Pouget et al. NUCLEAR MEDICINE AND BIOLOGY
- Health Care Administrative Costs in the United States and Canada, 2017
- (2020) David U. Himmelstein et al. ANNALS OF INTERNAL MEDICINE
- The radiosensitizer Onalespib increases complete remission in 177Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts
- (2020) Sara Lundsten et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
- (2020) Merry Jennifer Markham et al. JOURNAL OF CLINICAL ONCOLOGY
- Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study
- (2020) Arthur J A T Braat et al. LANCET ONCOLOGY
- Radiotheranostics: a roadmap for future development
- (2020) Ken Herrmann et al. LANCET ONCOLOGY
- The High Cost of Insulin in the United States: An Urgent Call to Action
- (2020) S. Vincent Rajkumar MAYO CLINIC PROCEEDINGS
- 225Ac-PSMA-617 for Therapy of Prostate Cancer
- (2020) Clemens Kratochwil et al. SEMINARS IN NUCLEAR MEDICINE
- Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of 177Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide CAPTEM)—First results for pancreas and updated midgut neuroendocrine tumors (pNETS, mNETS).
- (2020) Nick Pavlakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrating genomic features for non-invasive early lung cancer detection
- (2020) Jacob J. Chabon et al. NATURE
- Alterations of the tumor microenvironment in glioblastoma following radiation and temozolomide with or without bevacizumab
- (2020) Ryota Tamura et al. Annals of Translational Medicine
- Global Issues of Radiopharmaceutical Access and Availability: a Nuclear Medicine Global Initiative Project
- (2020) Cathy S Cutler et al. JOURNAL OF NUCLEAR MEDICINE
- Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer
- (2020) Johannes Czernin et al. JOURNAL OF NUCLEAR MEDICINE
- Radiopharmaceutical therapy in cancer: clinical advances and challenges
- (2020) George Sgouros et al. NATURE REVIEWS DRUG DISCOVERY
- The Effect of Advances in Lung-Cancer Treatment on Population Mortality
- (2020) Nadia Howlader et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I trial of docetaxel plus lutetium-177-labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer
- (2020) Jaspreet S. Batra et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP
- (2020) Carleen Cullinane et al. Scientific Reports
- Combination Strategies to Improve Targeted Radionuclide Therapy
- (2020) Tiffany Chan et al. JOURNAL OF NUCLEAR MEDICINE
- Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy
- (2020) Lisa Bodei et al. LANCET ONCOLOGY
- Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials
- (2020) Willemijn S M E Theelen et al. Lancet Respiratory Medicine
- Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial
- (2020) Etienne Garin et al. Lancet Gastroenterology & Hepatology
- Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer
- (2019) Wolfgang P. Fendler et al. JAMA Oncology
- Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Matthew Smith et al. LANCET ONCOLOGY
- Synergistic Effect of a Mesothelin Targeted Thorium-227 Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models
- (2019) Katrine Wickstroem et al. JOURNAL OF NUCLEAR MEDICINE
- State of the Art: Evaluating the Role of Theranostics in G3 Neuroendocrine Neoplasms
- (2019) Naj L. Waseem et al. JOURNAL OF NUCLEAR MEDICINE
- Dosimetry-based high-activity therapy with 131I-metaiodobenzylguanidine (131I-mIBG) and topotecan for the treatment of high-risk refractory neuroblastoma
- (2019) Jose Genolla et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Rituximab‐ PECC induction followed by 90 Y‐ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT : results from a phase II HOVON study
- (2019) Pieternella J. Lugtenburg et al. BRITISH JOURNAL OF HAEMATOLOGY
- Novel Target Selection for Nuclear Medicine Studies
- (2019) Sze Ting Lee et al. SEMINARS IN NUCLEAR MEDICINE
- The Future of Nuclear Medicine as an Independent Specialty
- (2019) Johannes Czernin et al. JOURNAL OF NUCLEAR MEDICINE
- Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety
- (2019) Sanjana Ballal et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- The Path to the Future: Education of Nuclear Medicine Therapeutic Specialists as Responsible Physicians
- (2019) Lisa Bodei et al. JOURNAL OF NUCLEAR MEDICINE
- EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides
- (2018) Daria Handkiewicz-Junak et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial
- (2018) Jonathan Strosberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of metabolism in cancer cell radioresistance and radiosensitization methods
- (2018) Le Tang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies—Part 1
- (2018) Sophie Poty et al. JOURNAL OF NUCLEAR MEDICINE
- Development of quinoline based theranostic ligands for the targeting of fibroblast activation protein
- (2018) Thomas Lindner et al. JOURNAL OF NUCLEAR MEDICINE
- Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
- (2018) Clemens Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
- (2018) Claudia Allemani et al. LANCET
- Targeting the tumour stroma to improve cancer therapy
- (2018) Kenneth C. Valkenburg et al. Nature Reviews Clinical Oncology
- Radiotheranostics in Cancer Diagnosis and Management
- (2018) Hossein Jadvar et al. RADIOLOGY
- Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial
- (2018) Martin Schlumberger et al. Lancet Diabetes & Endocrinology
- Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
- (2018) W. A. van der Zwan et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- A Multimodal Molecular Imaging Study Evaluates Pharmacological Alteration of the Tumor Microenvironment to Improve Radiation Response
- (2018) Yoichi Takakusagi et al. CANCER RESEARCH
- Efficacy and Safety of High-Specific-Activity I-131 MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
- (2018) Daniel A. Pryma et al. JOURNAL OF NUCLEAR MEDICINE
- Rapid modulation of PSMA expression by Androgen deprivation: Serial 68Ga PSMA-11 PET in men with hormone sensitive and castrate resistant prostate cancer commencing androgen blockade.
- (2018) Louise M Emmett et al. JOURNAL OF NUCLEAR MEDICINE
- Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour
- (2017) Anna Yordanova et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer
- (2017) Sarah M. Cheal et al. JOURNAL OF NUCLEAR MEDICINE
- Somatostatin Receptor 2–Targeting Compounds
- (2017) Daan A. Smit Duijzentkunst et al. JOURNAL OF NUCLEAR MEDICINE
- Pretargeted Imaging and Therapy
- (2017) Mohamed Altai et al. JOURNAL OF NUCLEAR MEDICINE
- Radiotherapy and immunotherapy: a beneficial liaison?
- (2017) Ralph R. Weichselbaum et al. Nature Reviews Clinical Oncology
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Direct detection of early-stage cancers using circulating tumor DNA
- (2017) Jillian Phallen et al. Science Translational Medicine
- The global decrease in cancer mortality: trends and disparities
- (2016) D. Hashim et al. ANNALS OF ONCOLOGY
- Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study
- (2016) S. Nilsson et al. ANNALS OF ONCOLOGY
- Myeloid neoplasms after chemotherapy and PRRT: myth and reality
- (2016) Lisa Bodei et al. ENDOCRINE-RELATED CANCER
- Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer
- (2016) Lisa Bodei et al. SEMINARS IN NUCLEAR MEDICINE
- Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
- (2016) Julie Nonnekens et al. Theranostics
- NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study
- (2015) Phillip G. Claringbold et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer
- (2015) Clemens Kratochwil et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
- (2014) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Reanalyses of Randomized Clinical Trial Data
- (2014) Shanil Ebrahim et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Targeted Chemoradiation in Metastatic Colorectal Cancer: A Phase I Trial of 131I-huA33 with Concurrent Capecitabine
- (2014) R. A. Herbertson et al. JOURNAL OF NUCLEAR MEDICINE
- Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
- (2014) Oliver Sartor et al. LANCET ONCOLOGY
- 90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial
- (2013) Franck Morschhauser et al. JOURNAL OF CLINICAL ONCOLOGY
- A Pretargeted PET Imaging Strategy Based on Bioorthogonal Diels-Alder Click Chemistry
- (2013) B. M. Zeglis et al. JOURNAL OF NUCLEAR MEDICINE
- Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
- (2013) Alan L. Ho et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- 68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging
- (2012) Matthias Eder et al. BIOCONJUGATE CHEMISTRY
- A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma
- (2012) Avichai Shimoni et al. CANCER
- mTOR Inhibitor RAD001 Promotes Metastasis in a Rat Model of Pancreatic Neuroendocrine Cancer
- (2012) S. E. Pool et al. CANCER RESEARCH
- [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH
- (2012) A. Afshar-Oromieh et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90–Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499
- (2012) Mitchell R. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- The Valley of Death in anticancer drug development: a reassessment
- (2012) David J. Adams TRENDS IN PHARMACOLOGICAL SCIENCES
- 90Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma
- (2011) A. K. Gopal et al. BLOOD
- Medical Spending Differences in the United States and Canada: The Role of Prices, Procedures, and Administrative Expenses
- (2011) Alexis Pozen et al. INQUIRY-THE JOURNAL OF HEALTH CARE ORGANIZATION PROVISION AND FINANCING
- Radioimmunotherapy in Non-Hodgkin Lymphoma: Opinions of Nuclear Medicine Physicians and Radiation Oncologists
- (2011) N. G. Schaefer et al. JOURNAL OF NUCLEAR MEDICINE
- Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours
- (2010) Phillip G. Claringbold et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Efficacy of Systemic Radionuclide Therapy with p-131I-Iodo-L-Phenylalanine Combined with External Beam Photon Irradiation in Treating Malignant Gliomas
- (2009) S. Samnick et al. JOURNAL OF NUCLEAR MEDICINE
- Therapeutic efficacy of177Lu-CHX-A″-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy
- (2008) Marcus P. Kelly et al. PROSTATE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now